Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Pfizer
Eli Lilly and Company
DL Analytics
Cancer Research UK
Corcept Therapeutics
Marengo Therapeutics, Inc.
Novartis
Stanford University
Karolinska Institutet
Mabwell (Shanghai) Bioscience Co., Ltd.